Anti-SARS-CoV-2 Nucleocapsid (NP) Human IgM ELISA Kit

Catalog No.

KAV18003

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant SARS-CoV-2 Nucleocapsid (NP) has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Anti-SARS-CoV-2 Nucleocapsid (NP) Human IgM present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgM antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-SARS-CoV-2 Nucleocapsid (NP) Human IgM bound in the initial step. The color development is stopped and the intensity of the color is measured.

Target

Nucleocapsid, NP

Applications

Used for the quantitative determination of Anti-SARS-CoV-2 Nucleocapsid (NP) Human IgM concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.63 - 1,000 ng/mL

Sensitivity

2.66 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.

Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination., PMID:38103966

SARS-CoV-2 seroprevalence determination in pets and camels in Egypt using multispecies enzyme-linked immunosorbent assay., PMID:38061231

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study., PMID:37437051

Accuracy of serological tests for COVID-19: A systematic review and meta-analysis., PMID:36589993

SARSPLEX: Multiplex Serological ELISA with a Holistic Approach., PMID:36560597

SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays., PMID:36146844

Evaluation of Performance of Detection of Immunoglobulin G and Immunoglobulin M Antibody Against Spike Protein of SARS-CoV-2 by a Rapid Kit in a Real-Life Hospital Setting., PMID:35558113

Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers., PMID:34601142

Development of a Nucleocapsid Protein-Based ELISA for Detection of Human IgM and IgG Antibodies to SARS-CoV-2., PMID:33869946

Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation., PMID:33869895

Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies., PMID:33660134

Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak., PMID:32681308

Document Download

Anti-SARS-CoV-2 Nucleocapsid (NP) Human IgM ELISA Kit.pdf